Biocartis Goes Public on Euronext, Raising $128M

Apr 28, 2015

|

Update: The story was updated on May 19 to include information about the underwriters exercising their overallotment option, increasing the proceed amount raised from the offering.

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis went public on Monday in Belgium, raising about €115 million ($128 million) in proceeds.

The company issued 8,695,652 shares of its common stock at €11.50 per share as part of its initial public offering. Its shares list on Euronext Brussels under ticker symbol "BCART."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Featured White Papers

Discovering Neuronal Cell Types

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

21

Featured Webinar

Evaluation & Implementation of NGS Liquid Biopsy Assays

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Main menu